Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats.
about
Interleukin-11 for induction of remission in Crohn's diseaseSTAT3, a Key Parameter of Cytokine-Driven Tissue Protection during Sterile Inflammation - the Case of Experimental Acetaminophen (Paracetamol)-Induced Liver DamageThe structure of human interleukin-11 reveals receptor-binding site features and structural differences from interleukin-6Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cellsDevelopment of a lyophilization formulation that preserves the biological activity of the platelet-inducing cytokine interleukin-11 at low concentrations.IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.Recent advances in inflammatory bowel disease.STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease?Recent developments in the pharmacological treatment of Crohn's disease.Biological response modifiers for the treatment of Crohn's disease.STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance.Biologic targeting in the treatment of inflammatory bowel diseases.Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer.Cytokine blockade in inflammatory bowel diseases.Translational research and efficacy of biologics in Crohn's disease: a cautionary tale.IL-11 signaling as a therapeutic target for cancer.Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentationRandomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.Interleukin-11 and interleukin-6 protect cultured human endothelial cells from H2O2-induced cell death.Effects of nitric oxide on gastric ulceration induced by nicotine and cold-restraint stressPro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol.Cytokines in inflammatory bowel disease.Activation of signal transducer and activator of transcription 1 (STAT1) is not sufficient for the induction of STAT1-dependent genes in endothelial cells. Comparison of interferon-gamma and oncostatin M.Role of epidermal growth factor and its receptor in chemotherapy-induced intestinal injury.Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.Desensitization of signaling by oncostatin M in human vascular cells involves cytoplasmic Tyr residue 759 in gp130 but is not mediated by either Src homology 2 domain-containing tyrosine phosphatase 2 or suppressor of cytokine signaling 3.Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis.Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.The therapeutic utility of Interleukin-11 in the treatment of inflammatory disease.New insights into the biological therapy of Crohn’s diseaseContribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for TreatmentSuppression of endotoxin-inducible cytokines in whole blood from human subjects following single dose of recombinant human interleukin-11
P2860
Q24200762-3F48443A-D7E8-40BF-B5CA-04A445E13B80Q26747404-3B809369-D7F2-45D2-850C-96C2F942CF41Q27695574-9E7F7A2F-8DAB-4AE6-8186-0629EED90008Q28236807-E6BF6FBF-FD1A-4359-A573-D7CA041964FBQ33331771-FC2ABAE7-E1E1-433A-B20C-746423B8E773Q33853636-F448A3E9-CFFE-46C2-B9C8-BC19BC6710DEQ34188405-3F3491BA-787A-404A-A822-818969D8AF9CQ35589806-6689B987-20A1-4639-94CD-2EB8CCF2C81BQ35753472-B0B9FA19-F1D3-40D4-9283-9AE587D40814Q35925597-5A224B14-7DDC-4FFF-8095-FE78320020F9Q36481079-D9CB9EF4-0436-4F0A-B13E-4BE12C14AD72Q37303206-C81ACFF3-D8DA-4CA4-A7C4-AA5B29C59115Q37387081-68BE1BD2-C98D-4694-8F38-E5665864DE8EQ37680981-0B04B173-7B6B-4E76-B335-46060E96FB29Q37770826-2FAAA14F-5BB1-4AEF-B221-838AD445AA4DQ37952792-21031152-BE50-45E4-8522-854382FABFCCQ38177338-82A474A9-94B8-4ED7-BEAD-4C03DE72BA5CQ38445355-C11D3B0F-50AC-4F04-9163-138F7D816C48Q39803727-2624341E-1294-4948-B6C7-AAA43D958902Q40480568-33097388-5EE7-463A-BC30-60131B3FF0C8Q40650232-D168099D-5647-4F64-9AD0-D616924AAD16Q41811909-78E10E24-0EFD-44BC-B865-046BCB5CE4BAQ42503626-59B7398C-D42A-46CE-AAAB-3E6FE06992F8Q43204450-1FEDA8D3-FD14-4652-8E08-6452D5EBB6E7Q43845847-A9DCE5E7-B25E-42D4-8DB2-2361DB718848Q43884235-6BFC8801-C7D8-4553-B31F-81A3F5A9CB5FQ43904258-7953E24C-5055-4DB9-8497-1E6B04E479ECQ44425106-B83A46B3-B12F-42C5-B287-1E6CB90C47DAQ45282194-40FF04E9-F7F8-47F3-904F-2EAA286E6E0AQ53499740-570B99B9-4113-4846-9B1F-37427CF31316Q53668241-2BC1FCF9-76D7-4274-85B0-171DC3894674Q57821547-32658129-F376-4F27-AB72-4D2218DB3782Q58799997-7CF270D2-0B84-4F4E-9F4C-9CC77F1AFD0DQ59296539-35EB458A-01C5-412B-AE1A-2633BB6D92CE
P2860
Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Protection by recombinant huma ...... l TNB-induced colitis in rats.
@en
Protection by recombinant huma ...... l TNB-induced colitis in rats.
@nl
type
label
Protection by recombinant huma ...... l TNB-induced colitis in rats.
@en
Protection by recombinant huma ...... l TNB-induced colitis in rats.
@nl
prefLabel
Protection by recombinant huma ...... l TNB-induced colitis in rats.
@en
Protection by recombinant huma ...... l TNB-induced colitis in rats.
@nl
P2093
P356
P1476
Protection by recombinant huma ...... l TNB-induced colitis in rats.
@en
P2093
P2888
P304
P356
10.1007/BF02087911
P577
1996-08-01T00:00:00Z
P6179
1035408083